No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
JMP Securities Maintains Rallybio(RLYB.US) With Buy Rating, Maintains Target Price $7
Rallybio Announces RLYB212 And RLYB332 Preclinical Data At The 66th ASH Annual Meeting
Rallybio Price Target Lowered to $7 From $8 at JMP Securities
Rallybio's RLYB116: Promising Developments and Buy Rating Driven by Enhanced Manufacturing and Potential in Phase 1 Trials
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025
Rallybio Flat on Release of New Findings
Unlock the Full List